[go: up one dir, main page]

MX2015011388A - Induccion de una respuesta inmunitaria de proteccion en recien nacidos y lactantes por una unica dosis elevada de mva. - Google Patents

Induccion de una respuesta inmunitaria de proteccion en recien nacidos y lactantes por una unica dosis elevada de mva.

Info

Publication number
MX2015011388A
MX2015011388A MX2015011388A MX2015011388A MX2015011388A MX 2015011388 A MX2015011388 A MX 2015011388A MX 2015011388 A MX2015011388 A MX 2015011388A MX 2015011388 A MX2015011388 A MX 2015011388A MX 2015011388 A MX2015011388 A MX 2015011388A
Authority
MX
Mexico
Prior art keywords
immune response
high dose
single high
neonates
infants
Prior art date
Application number
MX2015011388A
Other languages
English (en)
Other versions
MX376293B (es
Inventor
Paul Chaplin
Mark Suter
Cédric Cheminay
Ariane Volkmann
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Publication of MX2015011388A publication Critical patent/MX2015011388A/es
Publication of MX376293B publication Critical patent/MX376293B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)

Abstract

La invención hace referencia a composiciones y métodos para la inducción de una respuesta inmunitaria de protección contra un poxvirus en un recién nacido o lactante humano de menos de 6 meses de edad. La invención comprende la administración de una única dosis elevada de un MVA a un recién nacido o lactante humano de menos de 6 meses de edad, en la que la administración induce respuestas de protección de linfocitos T y B contra un poxvirus en el recién nacido o lactante humano.
MX2015011388A 2013-03-15 2014-03-14 Induccion de una respuesta inmunitaria de proteccion en recien nacidos y lactantes por una unica dosis elevada de mva. MX376293B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361788722P 2013-03-15 2013-03-15
PCT/EP2014/000693 WO2014139687A1 (en) 2013-03-15 2014-03-14 Single high dose of mva induces a protective immune response in neonates and infants

Publications (2)

Publication Number Publication Date
MX2015011388A true MX2015011388A (es) 2016-02-03
MX376293B MX376293B (es) 2025-03-07

Family

ID=50389388

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011388A MX376293B (es) 2013-03-15 2014-03-14 Induccion de una respuesta inmunitaria de proteccion en recien nacidos y lactantes por una unica dosis elevada de mva.

Country Status (17)

Country Link
US (1) US9707291B2 (es)
EP (2) EP2968524A1 (es)
JP (1) JP6480875B2 (es)
KR (1) KR102269491B1 (es)
CN (1) CN105101993A (es)
AU (4) AU2014231229A1 (es)
BR (1) BR112015021781A2 (es)
CA (1) CA2905569C (es)
EA (1) EA034825B1 (es)
HK (1) HK1216860A1 (es)
IL (1) IL241059B (es)
MX (1) MX376293B (es)
MY (1) MY175269A (es)
SG (2) SG10201707340XA (es)
UA (1) UA126785C2 (es)
WO (1) WO2014139687A1 (es)
ZA (1) ZA201507017B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102269491B1 (ko) * 2013-03-15 2021-06-25 버베리안 노딕 에이/에스 단회 고용량의 mva가 신생아 및 영아에서 보호 면역 반응을 유도
DK3116541T3 (da) 2014-03-12 2020-02-24 Bavarian Nordic As Anvendelse af olie-og-vand-emulsioner til forøgelse af b-celleresponser med modificerede vaccinia-ankara-virus
JP2023528984A (ja) * 2020-06-10 2023-07-06 バヴァリアン・ノルディック・アクティーゼルスカブ コロナウイルス病に対する組換え修飾ワクシニアウイルスアンカラ（ｍｖａ）ワクチン

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9117596D0 (en) * 1991-08-15 1991-10-02 John Gibson Lifting Gear Ltd Pulling system
US5471902A (en) * 1994-02-22 1995-12-05 Athenry Enterprises Limited Tuning system for pianos
AU2002231639B2 (en) * 2000-11-23 2007-01-04 Bavarian Nordic A/S Modified vaccinia ankara virus variant
US7628980B2 (en) * 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7445924B2 (en) * 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
US7097842B2 (en) * 2000-11-23 2006-08-29 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
BR0309339A (pt) * 2002-04-19 2005-03-08 Bavarian Nordic As Vìrus vaccinia modificado ankara para a vacinação de neonatos
US7501127B2 (en) * 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
PT1855720T (pt) * 2005-02-23 2016-12-14 Bavarian Nordic As Uso de um poxvírus modificado para a rápida indução de imunidade contra um poxvírus ou outros agentes infeciosos
US20100011451A1 (en) * 2006-09-08 2010-01-14 Paul Chaplin Phenotypic and genotypic differences of mva strains
WO2009152969A1 (en) * 2008-06-20 2009-12-23 Bavarian Nordic A/S Recombinant modified vaccinia virus measles vaccine
KR20120093941A (ko) * 2009-10-08 2012-08-23 버베리안 노딕 에이/에스 인간에서 ｈｉｖ에 대한 광범위한 ｔ-세포 반응의 생성
US9463238B2 (en) * 2011-12-09 2016-10-11 Bavarian Nordic A/S Recombinant poxvirus vector comprising tetanus toxin fragment C
EP2864487B1 (en) * 2012-06-22 2018-12-05 Bavarian Nordic A/S Poxviral vectors for low antibody response after a first priming immunization
CA2879915C (en) * 2012-08-01 2022-07-05 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine
KR102269491B1 (ko) * 2013-03-15 2021-06-25 버베리안 노딕 에이/에스 단회 고용량의 mva가 신생아 및 영아에서 보호 면역 반응을 유도

Also Published As

Publication number Publication date
EA201591803A1 (ru) 2016-02-29
JP6480875B2 (ja) 2019-03-13
CA2905569A1 (en) 2014-09-18
CA2905569C (en) 2023-07-25
CN105101993A (zh) 2015-11-25
BR112015021781A2 (pt) 2017-07-18
SG11201507192SA (en) 2015-10-29
NZ711569A (en) 2021-03-26
SG10201707340XA (en) 2017-10-30
ZA201507017B (en) 2018-12-19
UA126785C2 (uk) 2023-02-08
MY175269A (en) 2020-06-17
US9707291B2 (en) 2017-07-18
KR20150129027A (ko) 2015-11-18
EP3708187A1 (en) 2020-09-16
EA034825B1 (ru) 2020-03-25
IL241059B (en) 2020-10-29
HK1216860A1 (zh) 2016-12-09
AU2022235527A1 (en) 2022-10-13
JP2016514114A (ja) 2016-05-19
WO2014139687A1 (en) 2014-09-18
MX376293B (es) 2025-03-07
AU2022235527B2 (en) 2023-10-26
AU2019200977A1 (en) 2019-02-28
AU2020260472A1 (en) 2020-11-26
KR102269491B1 (ko) 2021-06-25
EP2968524A1 (en) 2016-01-20
IL241059A0 (en) 2015-11-30
AU2014231229A1 (en) 2015-09-17
US20160030551A1 (en) 2016-02-04

Similar Documents

Publication Publication Date Title
BR112015027281A8 (pt) usos de uma população de nanocarreadores sintéticos que são fixados a imunossupressores e composição compreendendo a referida população de nanocarreadores
BR112017001796A2 (pt) composições de flagelina e seus usos
CR20150242A (es) Terapia adyuvante con inhibidores de quinasa de la familia tec
TN2015000402A1 (fr) Methods for treating crohn's disease using an anti-il23 antibody
MX2017008813A (es) Polvo de coleopteros.
MX2015010880A (es) Combinacion de vacunacion e inhibicion de la trayectoria pd-1.
BR112016024352A2 (pt) ?cepa de listeria recombinante, listeria recombinante, composição farmacêutica, e, métodos de induzir uma resposta imune contra um tumor ou um câncer em um indivíduo humano e de listeria?
ECSP17043318A (es) Composición que contiene quitina y proteínas digeribles
PH12019502700A1 (en) Methods for treating psoriasis using an anti-il-23 antibody
PH12019502501A1 (en) Preterm infant formula containing butyrate and uses thereof
MX2013014485A (es) Vacuna bovinas y metodos.
BR112013018642A2 (pt) vacinas e composições contra streptococcus pneumoniae
BR112015022582A2 (pt) molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo
CL2018001826A1 (es) Composiciones que comprenden 2fl y lnnt para controlar la ingesta de alimento y el crecimiento en infantes o niños pequeños
BR112017015159A2 (pt) preparação e uso de produtos plaquetários
MX386374B (es) Composiciones farmacéuticas y alimenticias para inducir la saciedad y prolongar la saciedad en sujetos que lo necesiten.
BR112017028212A2 (pt) vacinação concomitante contra dengue e febre amarela
BR112017002440A2 (pt) vírus da diarreia epizoótica porcina mutante para utilização em uma vacina
MX377579B (es) Composición farmacéutica oral de isotretinoína con dosis baja y su proceso de preparación.
MX2016000107A (es) Osteopontina lactea de mamifero para mejorar la capacidad de respuesta inmunitaria.
CL2016001449A1 (es) Un sistema de nutrición adaptado a la edad para un infante
MX2015011388A (es) Induccion de una respuesta inmunitaria de proteccion en recien nacidos y lactantes por una unica dosis elevada de mva.
MX2015012548A (es) Metodos para estimular la maduracion de pulmones e intestinos infantiles.
UY35890A (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
AR100028A1 (es) Composiciones nutricionales que contienen ácido estearidónico

Legal Events

Date Code Title Description
FG Grant or registration